Genenta Science S.p.A (GNTA) Net Income (2023 - 2024)
Genenta Science S.p.A (GNTA) posted Net Income of $5.2 million for Q4 2024, down 0.93% sequentially from $5.3 million in Q4 2023, and down 0.93% YoY from $5.3 million in Q1 2024.
Genenta Science S.p.A (GNTA) Net Income (2023 - 2024) Analysis & Trends
Genenta Science S.p.A has reported Net Income for 2 years, with the latest figure at $5.2 million in Q4 2024.
- Quarterly Net Income fell 0.93% year-over-year to $5.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $5.2 million (down 50.23% YoY) and the FY2025 annual result came in at -$4.9 million, down 193.96% from the prior year.
- Net Income retreated to $5.2 million in Q4 2024 per GNTA's latest filing, from $5.3 million in the prior quarter.
- Over five years, Net Income peaked at $5.3 million in Q4 2023 and troughed at $5.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.21 Mn |
| Dec 31, 2023 | 5.26 Mn |